Generation and characterisation of adipose tissue-and umbilical-cord-derived mesenchymal stem cells expressing trail apoptotic ligand
Recent studies have shown that mesenchymal stem cells (MSCs) expressing TNFRelated Apoptosis Inducing Ligand (MSC-TRAIL) can eliminate both lung cancer cells and lung cancer stem cells efficiently. Although there have been several studies on the efficacy of various sources of MSC-TRAIL on several...
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2024
|
| Subjects: | |
| Online Access: | http://psasir.upm.edu.my/id/eprint/118119/ http://psasir.upm.edu.my/id/eprint/118119/1/118119.pdf |
| Summary: | Recent studies have shown that mesenchymal stem cells (MSCs) expressing TNFRelated
Apoptosis Inducing Ligand (MSC-TRAIL) can eliminate both lung cancer
cells and lung cancer stem cells efficiently. Although there have been several studies
on the efficacy of various sources of MSC-TRAIL on several cancers, there have been
very limited studies on which sources of MSCs are the most efficient in expressing
the TRAIL protein and biological properties of the engineered MSCs postmodification.
The engineered MSCs utilised in previous projects have varying genetic
constructs of the TRAIL-encoding lentiviruses transduced. Moreover, the period of
time required for ADMSCs to achieve a similar level of protein expression to
UCMSCs, was longer compared to UCMSCs in previous studies, suggesting
UCMSCs having higher expression efficiency compared to ADMSCs. This raises the
possibility of utilising other sources of MSCs, such as umbilical cord (UC) as a vector
for TRAIL. This project aims to generate adipose tissue (AD) and umbilical cord
(UC)-derived MSCs expressing TRAIL and characterise these cells post-modification.
The hypothesis of this study is TRAIL-expressing MSCs can be generated from AD
and UC, and these engineered cells retain the MSC characteristics. The methods
utilised are explained as follows. TRAIL encoding and empty vector lentivirus (LV)
were produced through the transfection of LV component plasmids into 293FT cells.
The virions were concentrated to >10⁶ transducing units (TU)/mL. The MSCs were
then transduced based on a range of MOIs. The TRAIL expression from the putative
ADMSC-TRAIL and putative UCMSC-TRAIL was validated using ELISA. The
engineered MSCs were then characterised through morphology observation, flow
cytometry analysis, and differentiation assay. Analysis of transduction efficiency
exhibited higher intensity of reporter gene-positive cells detected in putative UCMSCTRAIL
compared to putative ADMSC-TRAIL. Significantly higher TRAIL protein
was also detected in the protein lysate and conditioned medium of putative UCMSCTRAIL
than putative ADMSC-TRAIL, empty vector (MSC-EV), and wild-type MSCs
(MSC-WT). Moreover, all engineered MSCs retained their original characteristics
post-transduction. The putative MSC-TRAIL were able to differentiate into
adipocytes, osteocytes, and chondrocytes and maintained their MSC surface marker
expression (CD44, CD90, CD105, and CD73). In conclusion, the TRAIL expression
and characterisation analyses verified that the ADMSC-TRAIL and UCMSC-TRAIL
have been generated. UCMSCs are discovered to be potentially more effective as a
vector for TRAIL compared to ADMSCs. To further compare the potency of TRAILtransduced
MSCs in cancer therapy, functional assays incorporating MSC-TRAIL and
NSCLC cell lines can be performed in the future. |
|---|